The Experts below are selected from a list of 11745 Experts worldwide ranked by ideXlab platform
Hermann Brenner - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori infection chronic atrophic gastritis and risk of stomach and Esophagus Cancer results from the prospective population based esther cohort study
2020Co-Authors: Bernd Holleczek, Ben Schottker, Hermann BrennerAbstract:Helicobacter pylori (H. pylori) infection is considered as principal cause of gastric Cancer. It is further associated with a reduced risk of esophageal adenocarcinomas. In a large prospective population-based cohort study including 9,949 subjects with average observation time of 13.8 years, we assessed the risk of invasive gastric and esophageal Cancer according to H. pylori infection and presence of chronic atrophic gastritis (CAG). Incidence rates and hazard ratios (HR) derived by Cox proportional hazards models and adjusted for relevant confounders were derived by seroprevalence of H. pylori and cytotoxin-associated gene A (CagA) antibodies and presence of CAG based on serological markers at baseline, respectively. During follow-up, 30 cases of noncardia gastric Cancer and 33 cases of esophageal Cancer were observed. Infection by H. pylori without and with expression of CagA was associated with a 5.2-fold (95% confidence interval 1.00-27.1) and an 18.2-fold (4.3-77.4) increase of noncardia gastric Cancer incidence. A 0.65-fold decreased risk of esophageal adenocarcinomas (HR 0.35, 0.12-0.97) was observed among H. pylori-infected individuals. In participants infected with CagA expressed H. pylori, the presence of mild/moderate and severe CAG was associated with a 6.4-fold (1.3-31.0) and an 11.8-fold (3.1-45.4) increase of gastric Cancer incidence, respectively. The results of this prospective population-based cohort study may contribute relevant evidence to the ongoing research of H. pylori-related Cancers. The results may furthermore enhance the empirical basis for risk stratification among H. pylori-infected people and for recommendations regarding H. pylori screening and treatment among older adults in a Western population.
-
survival of stomach and Esophagus Cancer patients in germany in the early 21st century
2012Co-Authors: E Hiripi, Lina Jansen, Adam Gondos, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Sabine Luttmann, Alice Nennecke, Hermann BrennerAbstract:AbstractBackground. Esophagus and stomach Cancers are associated with poor prognosis. But most published population-based Cancer survival estimates for stomach and Esophagus Cancer refer to survival experience of patients diagnosed in the 1990s or earlier years. The aim of this study was to provide up-to-date survival estimates and trends for patients with stomach and Esophagus Cancer in Germany. Material and methods. Our analysis is based on data from 11 population-based Cancer registries, covering 33 million inhabitants. Patients diagnosed with stomach and Esophagus Cancer in 1997–2006 were included. Period analysis was used to derive five-year relative survival estimates and trends by age, sex, Cancer subsite, and stage for the time period of 2002–2006. German and US survival estimates were compared utilizing the SEER 13 database. Results. Overall age-standardized five-year relative survival was 31.8% and 18.3% for stomach and Esophagus Cancer, respectively, compared to 27.2% and 17.4% in the US. Survi...
Jens Overgaard - One of the best experts on this subject based on the ideXlab platform.
-
risk of second non breast Cancer after radiotherapy for breast Cancer a systematic review and meta analysis of 762 468 patients
2015Co-Authors: Trine Grantzau, Jens OvergaardAbstract:Abstract Background and purpose: Radiotherapy for breast Cancer both decreases loco-regional recurrence rates and improves overall survival. However, radiotherapy has also been associated with increased second Cancer risk at exposed sites. In this meta-analysis, we estimated the risk of second non-breast Cancers after radiotherapy for breast Cancer. Material and methods: The databases Medline/Pubmed, Cochrane, Embase and Cinahl were systematically searched, for cohort studies on second Cancer after radiotherapy for breast Cancer, from inception to August 1st 2013. Included studies were to report the relative risk (RR) of second Cancers comparing irradiated female breast Cancer patients to unirradiated patients. Primary endpoints were all second non-breast-Cancers and second Cancers of the lung, Esophagus, thyroid and second sarcomas. RRs were pooled using random-effects meta-analysis. Results: Thirteen studies comprising 762,468 breast Cancer patients were included in the meta-analysis. Five or more years after breast Cancer diagnosis radiotherapy was significantly associated with an increased risk of second non-breast Cancer RR 1.12 (95% confidence interval [CI] 1.06–1.19), second Cancer of the lung RR 1.39 (95% CI 1.28–1.51), Esophagus RR 1.53 (95% CI 1.01–2.31) and second sarcomas RR 2.53 (95% CI 1.74–3.70). The risk increased over time, and was highest 15 or more years after breast Cancer diagnosis, for second lung RR 1.66 (95% CI 1.36–2.01) and second Esophagus Cancer RR 2.17 (95% CI 1.11–4.25). There was no significant association between radiotherapy and second thyroid Cancer. Conclusions: Radiotherapy for breast Cancer is significantly associated with increased risks of second non-breast Cancer, overall and in organs adjacent to the previous treatment fields. Despite a relative small absolute risk, the growing number of long-time survivors after breast Cancer warrants the need for normal tissue sparing radiotherapy techniques.
Shuqing Chen - One of the best experts on this subject based on the ideXlab platform.
-
frequencies of poor metabolizers of cytochrome p450 2c19 in Esophagus Cancer stomach Cancer lung Cancer and bladder Cancer in chinese population
2004Co-Authors: Weixing Shi, Shuqing ChenAbstract:AIM: To investigate the association between cytochrome P450 2C19 (CYP2C19) gene polymorphism and Cancer susceptibility by genotyping of CYP2C19 poor metabolizers (PMs) in Cancer patients. METHODS: One hundred and thirty-five cases of Esophagus Cancer, 148 cases of stomach Cancer, 212 cases of lung Cancer, 112 cases of bladder Cancer and 372 controls were genotyped by allele specific amplification-polymerase chain reaction (ASA-PCR) for CYP2C19 PMs. The frequencies of PMs in Cancer groups and control group were compared. RESULTS: The frequencies of PMs of CYP2C19 were 34.1% (46/135) in the group of Esophagus Cancer patients, 31.8% (47/148) in the stomach Cancer patients, 34.4% (73/212) in the group of lung Cancer patients, only 4.5% (5/112) in the bladder Cancer patients and 14.0% (52/372) in control group. There were statistical differences between the Cancer groups and control group (Esophagus Cancer, χ2 = 25.65, P < 0.005, OR = 3.18, 95%CI = 2.005-5.042; stomach Cancer, χ2 = 21.70, P < 0.005, OR = 2.86, 95%CI = 1.820-4.501; lung Cancer, χ2 = 33.58, P < 0.005, OR = 3.23, 95%CI = 1.503-6.906; bladder Cancer, χ2 = 7.50, P < 0.01, OR = 0.288, 95%CI = 0.112-0.740). CONCLUSION: CYP2C19 PMs have a high incidence of Esophagus Cancer, stomach Cancer and lung Cancer, conversely they have a low incidence of bladder Cancer. It suggests that CYP2C19 may participate in the activation of procarcinogen of Esophagus Cancer, stomach Cancer and lung Cancer, but may involve in the detoxification of carcinogens of bladder Cancer.
Min Zhai - One of the best experts on this subject based on the ideXlab platform.
-
plce1 rs2274223 polymorphism and susceptibility to esophageal Cancer a meta analysis
2014Co-Authors: Li-yan Guo, Xia Zhao, Ning Yang, Bing Feng, Yan Zhang, Min ZhaiAbstract:Purpose: To investigate and study the relationship between the PLCE1 rs2274223 gene polymorphism and susceptibility to esophageal Cancer by meta-analysis. Materials and Methods: The literature was searched in Wanfang, CNKI, PubMed, CBM, Web of Science, MEDLINE, EMBASE, Springer, Elsevier and Cochrane databases from the date of January 1 st 2004 to April 1 st 2014 to collect case-control studies on the PLCE1 polymorphism and susceptibility to esophageal Cancer. For the population genotype distributions of both Esophagus Cancer and control groups, their odds ratios (ORs) and 95% confidence intervals (CIs) were taken as effect indexes. Disqualified studies were excluded. Odds ratios of PLCE1 rs2274223 genotype distributions in the group of patients with esophageal Cancer and the group of healthy control were calculated. The metaanalysis software, RevMan5.0, was applied for heterogeneity test, pooled OR and 95% confidence intervals. Sensitivity analysis and publication bias were also explored. Results: A total of twelve case-control studies were included, covering a total of 9, 912 esophageal Cancer cases and 13, 023 controls were included. The pooled odds ratio of PLCE1 rs2274223 genotype GA vs AA was 1.29 (95%CI=1.17~1.43), p<0.01, GG vs AA was 1.65 (95%CI=1.32~2.05), p<0.01, GG/GA vs AA was 1.30 (95%CI=1.16~1.46), p<0.01 and GG vs GA/AA was 1.48 (95%CI=1.22~1.80), p<0.01. The PLCE1 rs2274223 polymorphism was thus associated with risk of esophageal Cancer in all genetic models. In the stratified analysis by ethnicity, and source of controls, no significantly increased risk was observed for white persons. There was no obvious publication bias detected. Conclusions: This meta-analysis showed there was a significantly association between PLCE1 rs2274223 polymorphism and esophageal Cancer in yellow race populations. Due to some minor limitations, our findings should be confirmed in further studies.
Bernd Holleczek - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori infection chronic atrophic gastritis and risk of stomach and Esophagus Cancer results from the prospective population based esther cohort study
2020Co-Authors: Bernd Holleczek, Ben Schottker, Hermann BrennerAbstract:Helicobacter pylori (H. pylori) infection is considered as principal cause of gastric Cancer. It is further associated with a reduced risk of esophageal adenocarcinomas. In a large prospective population-based cohort study including 9,949 subjects with average observation time of 13.8 years, we assessed the risk of invasive gastric and esophageal Cancer according to H. pylori infection and presence of chronic atrophic gastritis (CAG). Incidence rates and hazard ratios (HR) derived by Cox proportional hazards models and adjusted for relevant confounders were derived by seroprevalence of H. pylori and cytotoxin-associated gene A (CagA) antibodies and presence of CAG based on serological markers at baseline, respectively. During follow-up, 30 cases of noncardia gastric Cancer and 33 cases of esophageal Cancer were observed. Infection by H. pylori without and with expression of CagA was associated with a 5.2-fold (95% confidence interval 1.00-27.1) and an 18.2-fold (4.3-77.4) increase of noncardia gastric Cancer incidence. A 0.65-fold decreased risk of esophageal adenocarcinomas (HR 0.35, 0.12-0.97) was observed among H. pylori-infected individuals. In participants infected with CagA expressed H. pylori, the presence of mild/moderate and severe CAG was associated with a 6.4-fold (1.3-31.0) and an 11.8-fold (3.1-45.4) increase of gastric Cancer incidence, respectively. The results of this prospective population-based cohort study may contribute relevant evidence to the ongoing research of H. pylori-related Cancers. The results may furthermore enhance the empirical basis for risk stratification among H. pylori-infected people and for recommendations regarding H. pylori screening and treatment among older adults in a Western population.
-
survival of stomach and Esophagus Cancer patients in germany in the early 21st century
2012Co-Authors: E Hiripi, Lina Jansen, Adam Gondos, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Sabine Luttmann, Alice Nennecke, Hermann BrennerAbstract:AbstractBackground. Esophagus and stomach Cancers are associated with poor prognosis. But most published population-based Cancer survival estimates for stomach and Esophagus Cancer refer to survival experience of patients diagnosed in the 1990s or earlier years. The aim of this study was to provide up-to-date survival estimates and trends for patients with stomach and Esophagus Cancer in Germany. Material and methods. Our analysis is based on data from 11 population-based Cancer registries, covering 33 million inhabitants. Patients diagnosed with stomach and Esophagus Cancer in 1997–2006 were included. Period analysis was used to derive five-year relative survival estimates and trends by age, sex, Cancer subsite, and stage for the time period of 2002–2006. German and US survival estimates were compared utilizing the SEER 13 database. Results. Overall age-standardized five-year relative survival was 31.8% and 18.3% for stomach and Esophagus Cancer, respectively, compared to 27.2% and 17.4% in the US. Survi...